Adagio Medical Reports Third Quarter 2025 Results

About this update from Adagio Medical Holdings, Inc

[{"type":"text","content":"Continued Momentum Toward PMA Submission of ULTC Technologies","length":61,"tagName":"p","attribs":{}},{"type":"text","content":"Recent Financing Positions Company to Execute Growth Strategy","length":61,"tagName":"p","attribs":{}},{"type":"text","content":"LAGUNA HILLS, Calif., November 12, 2025--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025.","length":328,"tagName":"p"},{"type":"text","content":"Recent Business Highlights:","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter development, with potential for up to $31 million in additional gross proceeds","length":362,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Completed enrollment of the 209-patient FULCRUM-VT Pivotal FDA Investigational Device Exemption ("IDE") trial intended to support the premarket approval ("PMA") application for the vCLAS™ System for ablation of ventricular tachycardia ("VT")","length":271,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced preliminary results from the FULCRUM-VT trial demonstrating 97% acute effectiveness and a favorable safety profile with the Company’s proprietary ultralow temperature technology","length":187,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strengthened executive leadership team with the appointment of Deborah Kaster as Chief Financial Officer, adding to her role as Chief Business Officer","length":150,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":970,"olType":false},{"type":"text","content":""Adagio made exceptional progress this quarter, with strong clinical momentum, a clear regulatory path and a solid pipeline," said Todd Usen, Chief Executive Officer of Adagio. "The successful completion of our financing provides the resources to advance o...

More updates from Adagio Medical Holdings, Inc